AstraZeneca’s Saphnelo (anifrolumab) has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union as a self-administered, ...
Clinical Director of the National Institute of Drug Abuse Dr. Lorenzo Leggio, said GLP-1 drugs' effect on the brain can help ...
The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...
TOKYO/CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a robust gross profit margin of 76.3% and strong financial health according to InvestingPro ...
7d
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. | Halozyme scoured very broadly for ...
TOKYO and CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...
The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule ...
Alteogen said on the 26th that it completed a Patent Cooperation Treaty (PCT) filing for its technology to develop a subcutaneous injection formulation of antibody-drug conjugate (ADC) medicines. An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback